References
Kirchhof P, Benussi S, Kotecha D et al (2016) ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962
Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, ESC Scientific Document Group (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39:1330–1393
Bolek T, Samoš M, Stančiaková L, Ivanková J, Škorňová I, Staško J, Galajda P, Kubisz P, Mokáň M (2017) The Impact of proton pump inhibition on dabigatran levels in patients with atrial fibrillation. Am J Ther. https://doi.org/10.1097/MJT.0000000000000599
Kuwayama T, Osanai H, Ajioka M, Tokuda K, Ohashi H, Tobe A, Yoshida T, Masutomi T, Kambara T, Inoue Y, Nakashima Y, Asano H, Sakai K (2017) Influence of proton pump inhibitors on blood dabigatran concentrations in Japanese patients with non-valvular atrial fibrillation. J Arrhythm 33:619–623
Ollier E, Hodin S, Basset T, Accassat S, Bertoletti L, Mismetti P, Delavenne X (2015) In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. Fundam Clin Pharmacol 29:604–614
Stangier J, Eriksson BI, Dahl OE et al (2005) Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 45:555–563
Kreutz R (2014) Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xainhibitor. Curr Clin Pharmacol 9:75–83
Raghavan N, Frost CE, Yu Z, He K, Zhang H, Humphreys WG, Pinto D, Chen S, Bonacorsi S, Wong PC, Zhang D (2009) Apixaban metabolism and pharmacokinetics after oral administration to humans. Drug Metab Dispos 37:74–81
Ogata K, Mendell-Harary J, Tachibana M, Masumoto H, Oguma T, Kojima M, Kunitada S (2010) Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol 50:743–753
Rottenstreich A, Barkai A, Arad A, Raccah BH, Kalish Y (2018) The effect of bariatric surgery on direct-acting oral anticoagulant drug levels. Thromb Res 163:190–195
Reilly PA, Lehr T, Haertter S et al (2014) RE-LY investigators. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (randomized evaluation of long-term anticoagulation therapy). J Am Coll Cardiol 63:321–328
Acknowledgments
The authors would like to thank Mr. Paul McCullough for proofreading.
Funding
This study was supported by project APVV (Slovak Research and Development Agency) 16-0020 and by research project UK/386/2018 of Comenius University in Bratislava.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval and inform consent
This research was done according to ethical standards and was approved by the local ethical committee (Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava). The patient agreed to participate in the research and signed an informed consent for study participation.
Rights and permissions
About this article
Cite this article
Bolek, T., Samoš, M., Škorňová, I. et al. How to proceed with long-term anticoagulation in patient after total gastrectomy and atrial fibrillation?. Eur J Clin Pharmacol 75, 285–286 (2019). https://doi.org/10.1007/s00228-018-2571-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-018-2571-9